Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UM1AI068636 | U.S. NIH Grant/Contract | View source | |
| R01AG054366 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
| National Institute on Aging (NIA) | NIH |
Not provided
Not provided
Not provided
Not provided
Aging with HIV is associated with earlier development of frailty (weakness) or disability, including loss of physical and muscle strength, and walking speed. Few treatments have been shown to prevent or slow these impairments in people with or without HIV. Some studies have suggested that the class of drugs called statins (for example, pitavastatin) might be helpful in slowing frailty or disability. This might happen by decreasing fat within the muscle or by decreasing inflammation markers (substances in the blood that determine how the body reacts to infection or irritation) in the blood. Other studies have shown that statins increase the risk of muscle aches and pains. This ancillary study was done to determine the impact of the drug pitavastatin on physical and muscle function.
The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE (A5332), subsequently referred to as REPRIEVE; NCT02344290) was a prospective, randomized, placebo-controlled, multicenter phase III trial to evaluate pitavastatin as prevention for cardiovascular disease events among people with HIV. PREPARE (A5361s, subsequently referred to as PREPARE) was an ancillary study of REPRIEVE to determine the effects of pitavastatin on physical and muscle function. The study enrolled participants:
The target sample size was 600 participants. The study was conducted at the REPRIEVE U.S. sites participating in the Mechanistic Substudy, and enrollment from the Mechanistic Substudy was prioritized to maximize the number of participants with computed tomography (CT) scan data performed as part of the Mechanistic Substudy.
Treatment groups (pitavastatin vs placebo) were defined according to randomization in REPRIEVE. Participants were enrolled into PREPARE blinded to their REPRIEVE treatment allocation. No intervention was provided in this ancillary study.
Originally the study duration was 48 months after participants' REPRIEVE entry. An additional visit was added at Month 60 due to missed in-person evaluations during the COVID-19 related restrictions in 2020 through early 2021.
Study visits were scheduled at PREPARE entry and at months 12, 24, 36, 48 and 60 after REPRIEVE entry. Each study visit included evaluation of physical function, frailty and self-reported physical activity and sedentary time. In addition, demographic and clinical data, laboratory specimens and CT scans collected as part of the main study REPRIEVE or its Mechanistic Substudy were used.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pitavastatin | Experimental | Participants who were randomized to pitavastatin in the main study REPRIEVE. |
|
| Placebo | Placebo Comparator | Participants who were randomized to placebo for pitavastatin in the main study REPRIEVE. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pitavastatin | Drug | One tablet (4 mg) taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Physical Function: Rate of Change in Chair Rise Rate | Chair rise rate was calculated as the number of chair stands performed divided by the time to complete 10 chair stands. Participants unable to attempt the test were assigned the worst time (9 seconds/stand for every stand not done). Linear mixed effects models for repeated measures were used to estimate annualized rate of change (slope), and the difference between treatment groups (interaction between slope and treatment group). Negative annualized rate of change reflects decline over time, positive improvement over time. | Entry and months 12, 24, 36, 48, 60 |
| Mechanistic: Rate of Change in Inflammatory Index Score (IIS) | Conditional on the positive findings on the primary physical function, the IIS score will be calculated as 1/3 log [interleukin-6 (IL-6)] + 2/3 log [soluble tumor necrosis factor receptor 1 (sTNFR-1)] using specimens collected as part of the main study REPRIEVE, and used to evaluate mechanistic pathways through which pitavastatin affects physical function. | Baseline and 12 months |
| Muscle Quality: Paraspinal Muscle Density | Paraspinal muscle (a back muscle) density was measured in Hounsfield units (HU, lower values indicate fattier muscle) from central reading of CT scans performed as part of A5333s, the Mechanistic Substudy of REPRIEVE. HU are used to measure the radiation attenuation of muscle in CT scans. Muscle tissue was identified as voxels with attenuation of -190 HU (very low density muscle, the fattiest) to 100 HU (high density muscle, the leanest). | Baseline and 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Physical Function: Rate of Change in Gait Speed | Gait speed was calculated as 4 meters divided by the average time to complete the 4-meter walk. Participants unable to attempt the test were assigned the worst gait speed (0 meters/second). Linear mixed effects models for repeated measures were used to estimate annualized rate of change (slope), and the difference between treatment groups (interaction between slope and treatment group). Negative annualized rate of change reflects decline over time, positive improvement over time. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Todd Brown, MD, PhD | Johns Hopkins University | Study Chair |
| Kristine Erlandson, MD | University of Colorado, Denver | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Alabama CRS (31788) | Birmingham | Alabama | 35294 | United States | ||
| University of Southern California (1201) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37368931 | Result | Erlandson KM, Umbleja T, Lu MT, Taron J, Ribaudo HJ, Overton ET, Presti RM, Haas DW, Sax PE, Yin MT, Zhai BK, Louis R, Upadhyay N, Eslami P, Douglas PS, Zanni MV, Fitch KV, Fulda ES, Fichtenbaum CJ, Malvestutto CD, Grinspoon SK, Brown TT. Associations of Muscle Density and Area With Coronary Artery Plaque and Physical Function. J Acquir Immune Defic Syndr. 2023 Oct 1;94(2):174-184. doi: 10.1097/QAI.0000000000003244. | |
| 38180893 | Result |
Not provided
Not provided
Not provided
Participants were enrolled from March 14, 2017 to February 6, 2019 at REPRIEVE U.S. sites participating in the REPRIEVE Mechanistic Substudy.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Pitavastatin | Participants who were randomized to pitavastatin in the main study REPRIEVE. |
| FG001 | Placebo | Participants who were randomized to placebo for pitavastatin in the main study REPRIEVE. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_ICF | Yes | No | Yes | Study Protocol and Informed Consent Form | Aug 20, 2021 |
Not provided
Not provided
Participants were randomized as part of REPRIEVE.
Not provided
Not provided
Not provided
| Placebos | Drug | One tablet taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up. |
|
| Entry and months 12, 24, 36, 48 and 60. |
| Physical Function: Rate of Change in Grip Strength | Grip strength was calculated as the average of three measurements in the dominant hand by Jamar Hydraulic Hand Dynamometer. Participants unable to attempt the test were assigned the worst result (0 kg). Linear mixed effects models for repeated measures were used to estimate annualized rate of change (slope), and the difference between treatment groups (interaction between slope and treatment group). Negative annualized rate of change reflects decline over time, positive improvement over time. | Entry and months 12, 24, 36, 48 and 60 |
| Physical Function: Rate of Change in Risk of Impairment According to Balance | Physical function impairment according to balance was defined as inability to hold single-leg stand for 30 seconds. Annualized risk of impairment year-over-year (ratio of risk per year, compared to risk per previous year) was estimated using log-binomial regression models for repeated data using GEE (relative risk of >1 reflects an increase in risk compared to previous year, relative risk <1 a decrease in risk compared to previous year). GEE (generalized estimating equations) is a statistical method for analyzing repeated measures, such as measurements of the outcome in participants at multiple time points. | Entry and months 12, 24, 36, 48, 60 |
| Physical Function: Rate of Change in Modified SPPB Score | Modified SPPB score (on scale from 0-worst to 3-best) was calculated as a sum of the following components each divided by the maximal possible performance: (1) chair rise rate (stands/second) divided by maximal performance of one stand/second; (2) proportion of total standing balance time calculated as the total time each of the semi-tandem, tandem and one-leg stand positions were held (maximum 30 seconds each) divided by 90 seconds; and (3) gait speed (meters/second) based on average of the 4-meter walk results divided by maximal performance of 2 meters/second. Linear mixed effects models for repeated measures were used to estimate annualized rate of change (slope), and the difference between treatment groups (interaction between slope and treatment group). Negative annualized rate of change reflects decline over time, positive improvement over time. | Entry and months 12, 24, 36, 48 and 60 |
| Physical Function: Rate of Change in Risk of Impairment According to SPPB | Physical function impairment according to composite Short Physical Performance Battery (SPPB, consisting of repeated chair stands, balance and gait speed tests) was defined as score <=10. In the absence of trend over time, average relative risk of impairment over follow-up time (ratio) was estimated using log-binomial regression models for repeated data using GEE (relative average risk of >1 reflects an increase in risk over follow-up time, relative average risk <1 a decrease in risk over follow-up time). GEE (generalized estimating equations) is a statistical method for analyzing repeated measures, such as measurements of the outcome in participants at multiple time points. | Entry and months 12, 24, 36, 48, 60 |
| Physical Function: Impairment According to DASI | Impairment was classified according to self-administered Duke Activity Status Index questionnaire score (on scale from 0-worst to 58.2-best) as no impairment (the max score of 58.2), some impairment (score of 34.7-<58.2), moderate impairment (9.95-<34.7) and severe impairment (0-<9.95). | Baseline, month 24 and end of REPRIEVE (average at 5.6 years) |
| Frailty Phenotype | Frailty Phenotype was defined based on the following components: (1) weight loss (self-report of unintentional weight loss of 10 or more pounds in the prior year), (2) exhaustion (experiencing at least three to four times per week the feeling that "everything I do is an effort" or "sometimes I cannot get going", (3) low physical activity (being "limited a lot" in response to the Short Form 36 question "does your health limit you in vigorous activities such as running, lifting heavy objects, or participating in strenuous sports?", (4) slow gait by average of two 4-meter walk times, and (5) weak grip by average of three measurements on a handheld Jamar dynamometer. Participants were classified as non-frail if they had no components present, pre-frail with one or two components present, and frail with three or more components present. | Entry and months 12, 24, 36, 48, 60 |
| Physical Activity: Frequency of <30 Minutes of Physical Activity 3 or More Days a Week | Self-reported physical activity evaluated by the questionnaire "Rapid Eating and Activity Assessment for Patients" (REAP) question 27: In an average week, how often do you do <30 minutes of physical activity 3 or more days a week? | Baseline and months 12, 24, 36, 48, 60 |
| Physical Activity: Frequency of Watching >2 Hours of TV or Videos a Day | Self-reported physical activity evaluated by the questionnaire "Rapid Eating and Activity Assessment for Patients" (REAP) question 28: In an average week, how often do you do watch >2 hours of TV or videos a day? | Baseline and months 12, 24, 36, 48, 60 |
| Muscle Quality: Pectoral Muscle Density | Pectoral (a chest muscle) density was measured in Hounsfield units (HU) from central reading of CT scans performed as part of A5333s, the Mechanistic Substudy of REPRIEVE. | Baseline and month 24 |
| Muscle Quality: Infraspinatus Muscle Density | Infraspinatus (an upper back muscle) density was measured in Hounsfield units (HU) from central reading of CT scans performed as part of A5333s, the Mechanistic Substudy of REPRIEVE. | Baseline and month 24 |
| Muscle Area: Paraspinal Muscle Area | Paraspinal muscle (a back muscle) area was measured from central reading of CT scans performed as part of A5333s, the Mechanistic Substudy of REPRIEVE. | Baseline and month 24 |
| Muscle Area: Pectoral Muscle Area | Pectoral muscle (a chest muscle) area was measured from central reading of CT scans performed as part of A5333s, the Mechanistic Substudy of REPRIEVE. | Baseline and month 24 |
| Muscle Area: Infraspinatus Muscle Area | Infraspinatus muscle (an upper back muscle) area was measured from central reading of CT scans performed as part of A5333s, the Mechanistic Substudy of REPRIEVE. | Baseline and month 24 |
| Mechanistic: Serum Concentrations of Biomarkers | Conditional on the positive findings on the primary physical function, select biomarkers including each individual biomarker of the IIS (IL-6, sTNFR-1) as well as other biomarkers implicated in the pathogenesis of physical function impairment or those that may mediate the effects of statins on systemic inflammation will be used to evaluate mechanistic pathways through which pitavastatin affects physical function. The specific list of biomarkers of interest will be finalized closer to the time of analysis, incorporating the developments in the field over the few years from study development to completion. | Baseline and month 12 |
| Los Angeles |
| California |
| 90033-1079 |
| United States |
| University of California, Los Angeles CARE Center CRS (601) | Los Angeles | California | 90035 | United States |
| Ucsd, Avrc Crs (701) | San Diego | California | 92103 | United States |
| Ucsf Aids Crs (801) | San Francisco | California | 94110 | United States |
| Harbor-UCLA Med. Ctr. CRS (603) | Torrance | California | 90502 | United States |
| University of Colorado Hospital CRS (6101) | Aurora | Colorado | 80045 | United States |
| 2701 Northwestern University CRS | Chicago | Illinois | 60611 | United States |
| Rush Univ. Med. Ctr. ACTG CRS (2702) | Chicago | Illinois | 60612 | United States |
| Johns Hopkins University CRS (201) | Baltimore | Maryland | 21205 | United States |
| Massachusetts General Hospital (MGH) CRS (101) | Boston | Massachusetts | 02114 | United States |
| Brigham and Women's Hosp. ACTG CRS (107) | Boston | Massachusetts | 02115 | United States |
| Washington University CRS (2101) | St Louis | Missouri | 63110 | United States |
| New Jersey Medical School Clinical Research Center CRS (31786) | Newark | New Jersey | 07103 | United States |
| Weill Cornell Chelsea CRS (7804) | New York | New York | 10010 | United States |
| Weill Med. College of Cornell Univ., The Cornell CTU -Chelsea (7803) | New York | New York | 10011 | United States |
| Columbia Physicians and Surgeons CRS (30329) | New York | New York | 10032 | United States |
| University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787) | Rochester | New York | 14642 | United States |
| Unc Aids Crs (3201) | Chapel Hill | North Carolina | 27516 | United States |
| Greensboro CRS (3203) | Greensboro | North Carolina | 27401 | United States |
| Univ. of Cincinnati CRS (2401) | Cincinnati | Ohio | 45267 | United States |
| Case CRS (2501) | Cleveland | Ohio | 44106 | United States |
| The Ohio State Univ. AIDS CRS (2301) | Columbus | Ohio | 43210 | United States |
| Hosp. of the Univ. of Pennsylvania CRS (6201) | Philadelphia | Pennsylvania | 19104 | United States |
| Pittsburgh CRS (1001) | Pittsburgh | Pennsylvania | 15213 | United States |
| The Miriam Hospital (TMH) ACTG CRS (2951) | Providence | Rhode Island | 02906 | United States |
| Vanderbilt Therapeutics CRS (3652) | Nashville | Tennessee | 37204 | United States |
| Trinity Health and Wellness Center CRS (31443) | Dallas | Texas | 75208 | United States |
| Houston AIDS Research Team (HART) CRS (31473) | Houston | Texas | 77030 | United States |
| University of Washington AIDS CRS (1401) | Seattle | Washington | 98104 | United States |
| Puerto Rico-AIDS CRS (5401) | San Juan | PR | 00935 | Puerto Rico |
| Abidi MZ, Umbleja T, Overton ET, Burdo T, Flynn JM, Lu MT, Taron J, Schnittman SR, Fitch KV, Zanni MV, Fichtenbaum CJ, Malvestutto C, Aberg JA, Fulda ES, Eckard AR, Manne-Goehler J, Tuan JJ, Ribaudo HJ, Douglas PS, Grinspoon SK, Brown TT, Erlandson KM. Cytomegalovirus IgG is Associated With Physical Function But Not Muscle Density in People With HIV. J Acquir Immune Defic Syndr. 2024 Apr 15;95(5):470-478. doi: 10.1097/QAI.0000000000003377. |
| 32645163 | Result | Umbleja T, Brown TT, Overton ET, Ribaudo HJ, Schrack JA, Fitch KV, Douglas PS, Grinspoon SK, Henn S, Arduino RC, Rodriguez B, Benson CA, Erlandson KM. Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE. J Infect Dis. 2020 Jul 9;222(Suppl 1):S52-S62. doi: 10.1093/infdis/jiaa249. |
| 39159048 | Derived | Erlandson KM, Umbleja T, Ribaudo HJ, Schrack JA, Overton ET, Fichtenbaum CJ, Fitch KV, Roa JC, Diggs MR, Wood K, Zanni MV, Bloomfield GS, Malvestutto C, Aberg JA, Rodriguez-Barradas MC, Morones RG, Breaux K, Douglas PS, Grinspoon SK, Brown TT. Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function. Clin Infect Dis. 2025 Feb 24;80(2):425-433. doi: 10.1093/cid/ciae422. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
All participants enrolled.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Pitavastatin | Participants who were randomized to pitavastatin in the main study REPRIEVE. |
| BG001 | Placebo | Participants who were randomized to placebo for pitavastatin in the main study REPRIEVE. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median | Inter-Quartile Range | years |
| |||||||||||||||
| Sex/Gender, Customized | Gender identity was reported by the participants. | Count of Participants | Participants |
| |||||||||||||||
| Sex: Female, Male | Sex assigned at birth. | Count of Participants | Participants |
| |||||||||||||||
| Ethnicity (NIH/OMB) | Ethnicity was reported by the participants. | Count of Participants | Participants |
| |||||||||||||||
| Race/Ethnicity, Customized | Race was reported by the participants. "Other" race includes participants who identified as native or indigenous to the enrollment region, as having more than one race, or as having an unknown race. | Count of Participants | Participants |
| |||||||||||||||
| Region of Enrollment | Number | participants |
| ||||||||||||||||
| Enrollment cohort | Enrollment cohort shows participants who enrolled into PREPARE concurrently with REPRIEVE (prospective enrollment) by co-enrollment in Mechanistic Substudy, and participants enrolled from REPRIEVE and Mechanistic Substudy within 24 months of their REPRIEVE enrollment (retrospective enrollment). | Count of Participants | Participants |
| |||||||||||||||
| CD4 cell count | CD4 cell count at REPRIEVE enrollment (prior to initiating study treatment). | Median | Inter-Quartile Range | cells/mm^3 |
| ||||||||||||||
| HIV-1 RNA | HIV-1 RNA at REPRIEVE enrollment (prior to initiating study treatment). HIV-1 RNA was captured if available through standard of care. | All participants enrolled with HIV-1 RNA result available through standard of care. | Count of Participants | Participants |
| ||||||||||||||
| Chair rise rate | Chair rise rate at PREPARE entry calculated based on the time to complete 10 repeated chair stands. For participants enrolled into PREPARE retrospectively within 24 months of REPRIEVE enrollment, this may not represent physical function at the time of REPRIEVE entry. | All participants enrolled with chair stand test completed at PREPARE entry. | Mean | Standard Deviation | rises per minute |
| |||||||||||||
| Gait speed | Gait speed at PREPARE entry calculated based on the average of two 4-meter walk times. For participants enrolled into PREPARE retrospectively within 24 months of REPRIEVE enrollment, this may not represent physical function at the time of REPRIEVE entry. | All participants enrolled with 4-meter walk test completed at PREPARE entry. | Mean | Standard Deviation | meters per second |
| |||||||||||||
| Grip strength | Grip strength at PREPARE entry calculated as the average of three measurements on a handheld Jamar dynamometer. For participants enrolled into PREPARE retrospectively within 24 months of REPRIEVE enrollment, this may not represent physical function at the time of REPRIEVE entry. | All participants enrolled with grip strength test completed at PREPARE entry. | Mean | Standard Deviation | kg |
| |||||||||||||
| Balance: Able to hold single-leg stand for 30 seconds | Ability to hold single-leg-stand for 30 seconds at PREPARE entry. For participants enrolled into PREPARE retrospectively within 24 months of REPRIEVE enrollment, this may not represent physical function at the time of REPRIEVE entry. | All participants enrolled with balance test completed at PREPARE entry. | Count of Participants | Participants |
| ||||||||||||||
| Physical Function Impairment by SPPB score | Impairment was classified as Short Physical Performance Battery (SPPB) score (≤10) and no impairment as score of 11-12 at PREPARE entry. For participants enrolled into PREPARE retrospectively within 24 months of REPRIEVE enrollment, this may not represent physical function at the time of REPRIEVE entry. | All participants enrolled with physical performance tests (repeated chair stands, 4-meter walk, balance) completed at PREPARE entry. | Count of Participants | Participants |
| ||||||||||||||
| Modified SPPB score | mSPPB score (ranging from 0-unable to perform to 3-maximal performance) at PREPARE entry calculated as a sum of the following components each divided by the maximal possible performance: (1) chair rise rate (stands/second) divided by maximal performance of one stand/second; (2) proportion of total standing balance time calculated as the total time each of the semi-tandem, tandem and one-leg stand positions were held (maximum 30 seconds each) divided by 90 seconds; and (3) gait speed (meters/second) based on average of the 4-meter walk results divided by maximal performance of 2 meters/second. | All participants enrolled with physical function tests (repeated chair stands, 4-meter walk, balance) completed at PREPARE entry. | Mean | Standard Deviation | units on a scale |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Physical Function: Rate of Change in Chair Rise Rate | Chair rise rate was calculated as the number of chair stands performed divided by the time to complete 10 chair stands. Participants unable to attempt the test were assigned the worst time (9 seconds/stand for every stand not done). Linear mixed effects models for repeated measures were used to estimate annualized rate of change (slope), and the difference between treatment groups (interaction between slope and treatment group). Negative annualized rate of change reflects decline over time, positive improvement over time. | All participants enrolled with any chair rise rate data available. | Posted | Mean | 95% Confidence Interval | rises/minute per year | Entry and months 12, 24, 36, 48, 60 |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Mechanistic: Rate of Change in Inflammatory Index Score (IIS) | Conditional on the positive findings on the primary physical function, the IIS score will be calculated as 1/3 log [interleukin-6 (IL-6)] + 2/3 log [soluble tumor necrosis factor receptor 1 (sTNFR-1)] using specimens collected as part of the main study REPRIEVE, and used to evaluate mechanistic pathways through which pitavastatin affects physical function. | The specimen testing was not performed. | Posted | Baseline and 12 months |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Muscle Quality: Paraspinal Muscle Density | Paraspinal muscle (a back muscle) density was measured in Hounsfield units (HU, lower values indicate fattier muscle) from central reading of CT scans performed as part of A5333s, the Mechanistic Substudy of REPRIEVE. HU are used to measure the radiation attenuation of muscle in CT scans. Muscle tissue was identified as voxels with attenuation of -190 HU (very low density muscle, the fattiest) to 100 HU (high density muscle, the leanest). | Participants who remained on study treatment at Month 24 (per-protocol set) and had data for this outcome available at both baseline and month 24. | Posted | Mean | Standard Deviation | HU | Baseline and 24 months |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Physical Function: Rate of Change in Gait Speed | Gait speed was calculated as 4 meters divided by the average time to complete the 4-meter walk. Participants unable to attempt the test were assigned the worst gait speed (0 meters/second). Linear mixed effects models for repeated measures were used to estimate annualized rate of change (slope), and the difference between treatment groups (interaction between slope and treatment group). Negative annualized rate of change reflects decline over time, positive improvement over time. | All participants enrolled with any gait speed data available. | Posted | Mean | 95% Confidence Interval | meters/second per year | Entry and months 12, 24, 36, 48 and 60. |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Physical Function: Rate of Change in Grip Strength | Grip strength was calculated as the average of three measurements in the dominant hand by Jamar Hydraulic Hand Dynamometer. Participants unable to attempt the test were assigned the worst result (0 kg). Linear mixed effects models for repeated measures were used to estimate annualized rate of change (slope), and the difference between treatment groups (interaction between slope and treatment group). Negative annualized rate of change reflects decline over time, positive improvement over time. | All participants enrolled with any grip strength data available. | Posted | Mean | 95% Confidence Interval | kg per year | Entry and months 12, 24, 36, 48 and 60 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Physical Function: Rate of Change in Risk of Impairment According to Balance | Physical function impairment according to balance was defined as inability to hold single-leg stand for 30 seconds. Annualized risk of impairment year-over-year (ratio of risk per year, compared to risk per previous year) was estimated using log-binomial regression models for repeated data using GEE (relative risk of >1 reflects an increase in risk compared to previous year, relative risk <1 a decrease in risk compared to previous year). GEE (generalized estimating equations) is a statistical method for analyzing repeated measures, such as measurements of the outcome in participants at multiple time points. | All participants enrolled with any balance data available. | Posted | Mean | 95% Confidence Interval | ratio per year | Entry and months 12, 24, 36, 48, 60 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Physical Function: Rate of Change in Modified SPPB Score | Modified SPPB score (on scale from 0-worst to 3-best) was calculated as a sum of the following components each divided by the maximal possible performance: (1) chair rise rate (stands/second) divided by maximal performance of one stand/second; (2) proportion of total standing balance time calculated as the total time each of the semi-tandem, tandem and one-leg stand positions were held (maximum 30 seconds each) divided by 90 seconds; and (3) gait speed (meters/second) based on average of the 4-meter walk results divided by maximal performance of 2 meters/second. Linear mixed effects models for repeated measures were used to estimate annualized rate of change (slope), and the difference between treatment groups (interaction between slope and treatment group). Negative annualized rate of change reflects decline over time, positive improvement over time. | All participants enrolled with any mSPPB data available. | Posted | Mean | 95% Confidence Interval | score on a scale per year | Entry and months 12, 24, 36, 48 and 60 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Physical Function: Rate of Change in Risk of Impairment According to SPPB | Physical function impairment according to composite Short Physical Performance Battery (SPPB, consisting of repeated chair stands, balance and gait speed tests) was defined as score <=10. In the absence of trend over time, average relative risk of impairment over follow-up time (ratio) was estimated using log-binomial regression models for repeated data using GEE (relative average risk of >1 reflects an increase in risk over follow-up time, relative average risk <1 a decrease in risk over follow-up time). GEE (generalized estimating equations) is a statistical method for analyzing repeated measures, such as measurements of the outcome in participants at multiple time points. | All participants enrolled with any SPPB data available. | Posted | Mean | 95% Confidence Interval | ratio | Entry and months 12, 24, 36, 48, 60 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Physical Function: Impairment According to DASI | Impairment was classified according to self-administered Duke Activity Status Index questionnaire score (on scale from 0-worst to 58.2-best) as no impairment (the max score of 58.2), some impairment (score of 34.7-<58.2), moderate impairment (9.95-<34.7) and severe impairment (0-<9.95). | All participants enrolled with DASI questionnaire completed at the given time point. | Posted | Count of Participants | Participants | Baseline, month 24 and end of REPRIEVE (average at 5.6 years) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Frailty Phenotype | Frailty Phenotype was defined based on the following components: (1) weight loss (self-report of unintentional weight loss of 10 or more pounds in the prior year), (2) exhaustion (experiencing at least three to four times per week the feeling that "everything I do is an effort" or "sometimes I cannot get going", (3) low physical activity (being "limited a lot" in response to the Short Form 36 question "does your health limit you in vigorous activities such as running, lifting heavy objects, or participating in strenuous sports?", (4) slow gait by average of two 4-meter walk times, and (5) weak grip by average of three measurements on a handheld Jamar dynamometer. Participants were classified as non-frail if they had no components present, pre-frail with one or two components present, and frail with three or more components present. | All participants enrolled with frailty phenotype data available. (Data availability at baseline and 12 depends on timing of PREPARE enrollment relative to REPRIEVE enrollment.) | Posted | Count of Participants | Participants | Entry and months 12, 24, 36, 48, 60 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Physical Activity: Frequency of <30 Minutes of Physical Activity 3 or More Days a Week | Self-reported physical activity evaluated by the questionnaire "Rapid Eating and Activity Assessment for Patients" (REAP) question 27: In an average week, how often do you do <30 minutes of physical activity 3 or more days a week? | All participants enrolled with REAP Question 27 data available. | Posted | Count of Participants | Participants | Baseline and months 12, 24, 36, 48, 60 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Physical Activity: Frequency of Watching >2 Hours of TV or Videos a Day | Self-reported physical activity evaluated by the questionnaire "Rapid Eating and Activity Assessment for Patients" (REAP) question 28: In an average week, how often do you do watch >2 hours of TV or videos a day? | All participants enrolled with REAP Question 28 data available. | Posted | Count of Participants | Participants | Baseline and months 12, 24, 36, 48, 60 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Muscle Quality: Pectoral Muscle Density | Pectoral (a chest muscle) density was measured in Hounsfield units (HU) from central reading of CT scans performed as part of A5333s, the Mechanistic Substudy of REPRIEVE. | Participants who remained on study treatment at Month 24 (per-protocol set) and had data for this outcome available at both baseline and month 24. | Posted | Mean | Standard Deviation | HU | Baseline and month 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Muscle Quality: Infraspinatus Muscle Density | Infraspinatus (an upper back muscle) density was measured in Hounsfield units (HU) from central reading of CT scans performed as part of A5333s, the Mechanistic Substudy of REPRIEVE. | Participants who remained on study treatment at Month 24 (per-protocol set) and had data for this outcome available at both baseline and month 24. | Posted | Mean | Standard Error | HU | Baseline and month 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Muscle Area: Paraspinal Muscle Area | Paraspinal muscle (a back muscle) area was measured from central reading of CT scans performed as part of A5333s, the Mechanistic Substudy of REPRIEVE. | Participants who remained on study treatment at Month 24 (per-protocol set) and had data for this outcome available at both baseline and month 24. | Posted | Mean | Standard Deviation | cm^2/m | Baseline and month 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Muscle Area: Pectoral Muscle Area | Pectoral muscle (a chest muscle) area was measured from central reading of CT scans performed as part of A5333s, the Mechanistic Substudy of REPRIEVE. | Participants who remained on study treatment at Month 24 (per-protocol set) and had data for this outcome available at both baseline and month 24. | Posted | Mean | Standard Deviation | cm^2/m | Baseline and month 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Muscle Area: Infraspinatus Muscle Area | Infraspinatus muscle (an upper back muscle) area was measured from central reading of CT scans performed as part of A5333s, the Mechanistic Substudy of REPRIEVE. | Participants who remained on study treatment at Month 24 (per-protocol set) and had data for this outcome available at both baseline and month 24. | Posted | Mean | Standard Deviation | cm^2/m | Baseline and month 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mechanistic: Serum Concentrations of Biomarkers | Conditional on the positive findings on the primary physical function, select biomarkers including each individual biomarker of the IIS (IL-6, sTNFR-1) as well as other biomarkers implicated in the pathogenesis of physical function impairment or those that may mediate the effects of statins on systemic inflammation will be used to evaluate mechanistic pathways through which pitavastatin affects physical function. The specific list of biomarkers of interest will be finalized closer to the time of analysis, incorporating the developments in the field over the few years from study development to completion. | The specimen testing was not done. | Posted | Baseline and month 12 |
|
|
For all-cause mortality: from entry to Month 60
There was no adverse event data collection in PREPARE.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Pitavastatin | Participants who were randomized to pitavastatin in the main study REPRIEVE. | 7 | 316 | 0 | 0 | 0 | 0 |
| EG001 | Placebo | Participants who were randomized to placebo for pitavastatin in the main study REPRIEVE. | 10 | 286 | 0 | 0 | 0 | 0 |
Not provided
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| ACTG Clinicaltrials.gov Coordinator | ACTG Network Coordinating Center, Social and Scientific Systems, a DLH Holdings Company | (301) 628-3348 | ACTGCT.gov@fstrf.org |
| Aug 16, 2023 |
| Prot_ICF_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Aug 5, 2021 | Aug 6, 2024 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| C108475 | pitavastatin |
Not provided
Not provided
Not provided
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
| Participants |
|
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Some impairment |
|
| Moderate impairment |
|
| Severe impairment |
|
| Some impairment |
|
| Moderate impairment |
|
| Severe impairment |
|
| Pre-frail |
|
| Frail |
|
| Pre-frail |
|
| Frail |
|
| Pre-frail |
|
| Frail |
|
| Pre-frail |
|
| Frail |
|
| Pre-frail |
|
| Frail |
|
| Sometimes |
|
| Usually/often |
|
| Sometimes |
|
| Usually/often |
|
| Sometimes |
|
| Usually/often |
|
| Sometimes |
|
| Usually/often |
|
| Sometimes |
|
| Usually/often |
|
| Sometimes |
|
| Usually/often |
|
| Sometimes |
|
| Usually/often |
|
| Sometimes |
|
| Usually/often |
|
| Sometimes |
|
| Usually/often |
|
| Sometimes |
|
| Usually/often |
|